Romuald Bellmann1, Piotr Smuszkiewicz2. 1. Clinical Pharmacokinetics Unit, Division of Intensive Care and Emergency Medicine, Department of Internal Medicine I, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. romuald.bellmann@i-med.ac.at. 2. Department of Anesthesiology, Intensive Therapy and Pain Treatment, University Hospital, Poznań, Poland.
Abstract
INTRODUCTION: Because of the high mortality of invasive fungal infections (IFIs), appropriate exposure to antifungals appears to be crucial for therapeutic efficacy and safety. MATERIALS AND METHODS: This review summarises published pharmacokinetic data on systemically administered antifungals focusing on co-morbidities, target-site penetration, and combination antifungal therapy. CONCLUSIONS AND DISCUSSION: Amphotericin B is eliminated unchanged via urine and faeces. Flucytosine and fluconazole display low protein binding and are eliminated by the kidney. Itraconazole, voriconazole, posaconazole and isavuconazole are metabolised in the liver. Azoles are substrates and inhibitors of cytochrome P450 (CYP) isoenzymes and are therefore involved in numerous drug-drug interactions. Anidulafungin is spontaneously degraded in the plasma. Caspofungin and micafungin undergo enzymatic metabolism in the liver, which is independent of CYP. Although several drug-drug interactions occur during caspofungin and micafungin treatment, echinocandins display a lower potential for drug-drug interactions. Flucytosine and azoles penetrate into most of relevant tissues. Amphotericin B accumulates in the liver and in the spleen. Its concentrations in lung and kidney are intermediate and relatively low myocardium and brain. Tissue distribution of echinocandins is similar to that of amphotericin. Combination antifungal therapy is established for cryptococcosis but controversial in other IFIs such as invasive aspergillosis and mucormycosis.
INTRODUCTION: Because of the high mortality of invasive fungal infections (IFIs), appropriate exposure to antifungals appears to be crucial for therapeutic efficacy and safety. MATERIALS AND METHODS: This review summarises published pharmacokinetic data on systemically administered antifungals focusing on co-morbidities, target-site penetration, and combination antifungal therapy. CONCLUSIONS AND DISCUSSION: Amphotericin B is eliminated unchanged via urine and faeces. Flucytosine and fluconazole display low protein binding and are eliminated by the kidney. Itraconazole, voriconazole, posaconazole and isavuconazole are metabolised in the liver. Azoles are substrates and inhibitors of cytochrome P450 (CYP) isoenzymes and are therefore involved in numerous drug-drug interactions. Anidulafungin is spontaneously degraded in the plasma. Caspofungin and micafungin undergo enzymatic metabolism in the liver, which is independent of CYP. Although several drug-drug interactions occur during caspofungin and micafungin treatment, echinocandins display a lower potential for drug-drug interactions. Flucytosine and azoles penetrate into most of relevant tissues. Amphotericin B accumulates in the liver and in the spleen. Its concentrations in lung and kidney are intermediate and relatively low myocardium and brain. Tissue distribution of echinocandins is similar to that of amphotericin. Combination antifungal therapy is established for cryptococcosis but controversial in other IFIs such as invasive aspergillosis and mucormycosis.
Authors: David Andes; Paul G Ambrose; Jeffrey P Hammel; Scott A Van Wart; Varsha Iyer; Daniel K Reynolds; Donald N Buell; Laura L Kovanda; Sujata M Bhavnani Journal: Antimicrob Agents Chemother Date: 2011-02-07 Impact factor: 5.191
Authors: John H Rex; Peter G Pappas; Adolf W Karchmer; Jack Sobel; John E Edwards; Susan Hadley; Corstiaan Brass; Jose A Vazquez; Stanley W Chapman; Harold W Horowitz; Marcus Zervos; David McKinsey; Jeannette Lee; Timothy Babinchak; Robert W Bradsher; John D Cleary; David M Cohen; Larry Danziger; Mitchell Goldman; Jesse Goodman; Eileen Hilton; Newton E Hyslop; Daniel H Kett; Jon Lutz; Robert H Rubin; W Michael Scheld; Mindy Schuster; Bryan Simmons; David K Stein; Ronald G Washburn; Linda Mautner; Teng-Chiao Chu; Helene Panzer; Rebecca B Rosenstein; Jenia Booth Journal: Clin Infect Dis Date: 2003-05-08 Impact factor: 9.079
Authors: Eric Milefchik; Mary Ann Leal; Richard Haubrich; Samuel A Bozzette; Jeremiah G Tilles; John M Leedom; J Allen McCutchan; Robert A Larsen Journal: Med Mycol Date: 2008-06 Impact factor: 4.076
Authors: R Herbrecht; J Maertens; L Baila; M Aoun; W Heinz; R Martino; S Schwartz; A J Ullmann; L Meert; M Paesmans; O Marchetti; H Akan; L Ameye; M Shivaprakash; C Viscoli Journal: Bone Marrow Transplant Date: 2010-01-11 Impact factor: 5.483
Authors: Yingjun Li; Kalyan Kumar Pasunooti; Hanjing Peng; Ruo-Jing Li; Wei Q Shi; Wukun Liu; Zhiqiang Cheng; Sarah A Head; Jun O Liu Journal: ACS Med Chem Lett Date: 2020-04-08 Impact factor: 4.345
Authors: A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl Journal: Stud Mycol Date: 2021-05-10 Impact factor: 16.097
Authors: S Luque; W Hope; N Campillo; R Muñoz-Bermúdez; L Sorli; J Barceló-Vidal; E González-Colominas; F Alvarez-Lerma; J R Masclans; M Montero; J P Horcajada; S Grau Journal: Antimicrob Agents Chemother Date: 2019-06-24 Impact factor: 5.191
Authors: Kimberley A Savage; Maria del Carmen Parquet; David S Allan; Ross J Davidson; Bruce E Holbein; Elizabeth A Lilly; Paul L Fidel Journal: Antimicrob Agents Chemother Date: 2018-07-27 Impact factor: 5.191